MapperHealth, LLC — SEC Form D Filing
MapperHealth, LLC filed an SEC Form D on May 15, 2026, reporting $8.20M raised in Health Technology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- May 15, 2026
- Amount reported
- $8.20M
- Round stage
- Seed
- Industry
- Health Technology
- Website
- https://www.rxmapper.com/
What the company does
Securities: SAFE. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Current medications may not be effective or safe for all individuals due to genetic differences, which can lead to poor health outcomes. Patients struggle with ineffective treatments, high costs, and complex medication regimens.
Solution
RxMapper provides personalized medication recommendations by analyzing a patient's DNA to determine which drugs are likely to be safe and effective for them. This platform offers telehealth consults and is designed to improve health outcomes and reduce costs.
Why now
The increasing demand for personalized medicine and more effective treatment options make this an ideal time for RxMapper's services.
Verdict
Investors backed MapperHealth because the narrative presented a timely demand for personalized medicine amidst a growing health crisis, not because the competitive landscape seemed entirely favorable. They were implicitly betting on the inevitability of DNA-driven healthcare advancements gaining traction with health plan administrators. The limited upside lies in execution risk given the crowded market with established players like 23andMe, implying that unique differentiation is crucial for long-term sustainability.
Source: SEC EDGAR Form D filing